Multiple Sclerosis Journal, Год журнала: 2023, Номер 29(10), С. 1204 - 1205
Опубликована: Сен. 1, 2023
Язык: Английский
Alzheimer s & Dementia Translational Research & Clinical Interventions, Год журнала: 2025, Номер 11(1)
Опубликована: Янв. 1, 2025
Abstract INTRODUCTION Biomarkers (BMs) are valuable tools to facilitate early diagnosis of (subtypes of) diseases, improve patient selection and stratification, detect therapeutic effects or safety concerns. This study explores the extent which BMs utilized in development treatments for neurodegenerative diseases (NDDs), as well topics discussion regarding regulatory advice‐ decision‐making processes sharing BM‐related data. METHODS The European Medicines Agency's marketing authorization application (MAA), qualification (QA/QO), scientific advice (SA) procedures NDDs were screened, those that mention analyzed. Data extracted on intended disease, BM type, context use proposed by applicants. categorized based both nature function. RESULTS In total, 105 discussed analyzed, 57 SAs (January 2020 December 2022), 19 QAs/QOs 2008 2023), 29 MAAs 1995 2023). majority involved Alzheimer's disease (AD; n = 30), Parkinson's (PD; 9), multiple sclerosis (MS; 33). Imaging most common type discussed, used pharmacodynamic/response measures. acceptance role differed between AD, PD, MS, other NDDs. example, diagnostic guiding commonly whereas imaging (particularly lesions) generally accepted supportive/secondary endpoints. DISCUSSION Despite established certain BMs, mainly there remains a major need more precise reliable accuracy treatment monitoring To implement novel new eventually clinical practice, robust evidence bases showcasing biological plausibility clear benefits essential. Collaboration data‐sharing among stakeholders is vital generating this enhancing understanding management Highlights applications procedures. One hundred five analyzed discuss biomarkers. We found biomarkers differ per disease. Biological plausibility/clinical essential biomarker implementation.
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(10), С. 5412 - 5412
Опубликована: Май 15, 2024
Multiple sclerosis is a chronic immune-mediated disorder of the central nervous system with high heterogeneity among patients. In clinical setting, one main challenges proper and early diagnosis for prediction disease activity. Current based on integration clinical, imaging, laboratory results, latter presence intrathecal IgG oligoclonal bands in cerebrospinal fluid whose detection via isoelectric focusing followed by immunoblotting represents gold standard. Intrathecal synthesis can also be evidenced measurement kappa free light chains fluid, which has reached similar diagnostic accuracy compared to that identification patients multiple sclerosis; moreover, recent studies have highlighted its value activity prediction. This strategy significant advantages as using band detection, even though some issues remain open. Here, we discuss current methods applied analysis achieve most accurate follow-up prognosis evaluation. addition, describe new promising biomarkers, currently under investigation, could contribute both better monitoring therapeutic treatment response.
Язык: Английский
Процитировано
4
International Journal of MS Care, Год журнала: 2025, Номер 27(Q1), С. 90 - 94
Опубликована: Март 24, 2025
ABSTRACT BACKGROUND: Advances in serum proteomics have provided more precise tools for the characterization of multiple sclerosis (MS) and enabled enhanced clinical management disease. The multivariate proteomic Multiple Sclerosis Disease Activity (MSDA) test has been analytically clinically validated. METHODS: This is a single-center retrospective case series. Four women with MS were monitored between 2022 2023 up to 2 MSDA time points. Their full histories exams, along treatment MRI changes, collected tests. RESULTS: Patients' baseline follow-up scores consistent disease activity, response, stability. CONCLUSIONS: We provide real-world series show that could help determine activity at throughout course. differentiate stable vs active patients monitor DMT response.
Язык: Английский
Процитировано
0
Journal of Neurology Neurosurgery & Psychiatry, Год журнала: 2023, Номер unknown, С. jnnp - 332251
Опубликована: Ноя. 8, 2023
Background We aimed to investigate the potential of serum biomarker levels predict disability progression in a multicentric real-world cohort patients with primary progressive multiple sclerosis (PPMS). Methods A total 141 PPMS from 18 European MS centres were included. Disability was investigated using change Expanded Status Scale (EDSS) score over three time intervals: baseline 2 years, 6 years and last follow-up. Serum neurofilament light chain (sNfL), glial fibrillar acidic protein (sGFAP) chitinase 3-like 1 (sCHI3L1) measured single-molecule array assays at baseline. Correlations between levels, biomarkers age quantified Spearman’s r. Univariable multivariable linear models performed assess associations EDSS different periods. Results Median (IQR) 52.9 (46.4–58.5) 58 (41.1%) men. follow-up 9.1 (7.0–12.6) years. Only 8 (5.7%) received treatment during sNfL sGFAP moderately correlated (r=0.43) both weakly sCHI3L1 (r=0.19 r=0.17, respectively). In analyses, associated changes across all However, when analysis restricted non-inflammatory according clinical radiological parameters (n=64), only remained future change. Conclusions Levels sNfL, are prognostic PPMS, being CHI3L1 findings less dependent on inflammatory component disease progression.
Язык: Английский
Процитировано
9
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Авг. 19, 2024
Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system resulting in progressive disability accumulation. As there no cure available yet for MS, primary therapeutic objective to reduce relapses and slow down progression as early possible during disease maintain and/or improve health-related quality life. However, optimizing treatment people with MS (pwMS) complex challenging due many factors involved particular, high degree clinical sub-clinical heterogeneity among pwMS. In this paper, we discuss these different challenges complicating optimization pwMS well how shift towards more pro-active, data-driven personalized medicine approach could potentially patient outcomes We describe 'Clinical Impact through AI-assisted Care' (CLAIMS) project serves recent example realize such development platform that offers holistic view all relevant data biomarkers, then using enable AI-supported prognostic modelling.
Язык: Английский
Процитировано
3
Annals of Clinical and Translational Neurology, Год журнала: 2024, Номер 11(9), С. 2485 - 2498
Опубликована: Авг. 26, 2024
Circulating metabolite levels are altered in multiple sclerosis (MS) and associated with MS severity. However, how metabolic profiles shift following highly efficacious therapies, like ocrelizumab remains unclear.
Язык: Английский
Процитировано
2
Neurological Sciences, Год журнала: 2024, Номер 45(7), С. 3061 - 3068
Опубликована: Фев. 19, 2024
Язык: Английский
Процитировано
1
Neurologie up2date, Год журнала: 2024, Номер 07(01), С. 29 - 44
Опубликована: Март 1, 2024
Biomarker gelten als Schlüsselelement für die Umsetzung von Präzisionsmedizin. Technische Fortschritte in der Quantifizierbarkeit ZNS-Molekülen im peripheren Blut und Design klinischen Studien zur Identifizierung Validierung Biomarkern haben den letzten Jahren zu einer starken Dynamik Biomarkerentwicklung sowohl bei entzündlichen auch degenerativen Erkrankungen des Nervensystems geführt. Die vorliegende Übersicht fasst aktuellen Stand Entwicklungslinien molekularen neurologischen zusammen.
Процитировано
1
Computers in Biology and Medicine, Год журнала: 2024, Номер 175, С. 108416 - 108416
Опубликована: Апрель 17, 2024
In light of extensive work that has created a wide range techniques for predicting the course multiple sclerosis (MS) disease, this paper attempts to provide an overview these approaches and put forth alternative way predict disease progression. For purpose, existing methods estimating have been categorized into clinical, radiological, biological, computational or artificial intelligence-based markers. Weighing weaknesses strengths prognostic groups is profound method yet in need works directly at level diseased connectivity. Therefore, we propose using models combination with established connectomes as predictive tool MS trajectories. The fundamental conduction-based Hodgkin-Huxley model emerged promising from examining studies. advantage certain properties connectomes, such neuronal connection weights, spatial distances, adjustments signal transmission rates, can be taken account. It precisely are particularly altered strong implications processing, transmission, interactions signaling patterns. (HH) equations point-neuron used propagation inside small network. objective change conduction parameter neuron model, replicate changes myelin observe dynamics across initially validated different lengths, values, weights through three nodal connections. Later, individual factors incorporated network simulated mimic condition MS. pattern observed after inducing parameters nodes compared against control obtained before applied varies expected by adapting input conditions. Similarly, when connectome, could give insight This approach opened up new path explore progression its preliminary state, but future vision apply providing better clinical tool.
Язык: Английский
Процитировано
1
Journal of Personalized Medicine, Год журнала: 2024, Номер 14(8), С. 815 - 815
Опубликована: Июль 31, 2024
MicroRNA-150 (miR-150) plays a critical role in immune regulation and has been implicated autoimmune diseases like Multiple Sclerosis (MS). This review aims to evaluate miR-150's potential as biomarker for MS, necessitating this consolidate current evidence highlight utility improving diagnostic accuracy monitoring disease progression.
Язык: Английский
Процитировано
1